{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:11:35Z","timestamp":1779149495851,"version":"3.51.4"},"reference-count":43,"publisher":"The Endocrine Society","issue":"6","license":[{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Swiss National Science Foundation","doi-asserted-by":"publisher","award":["32473B162608"],"award-info":[{"award-number":["32473B162608"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Young Talents in Clinical Research"},{"DOI":"10.13039\/501100008485","name":"Swiss Academy of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008485","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005688","name":"Gottfried und Julia Bangerter-Rhyner Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005688","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016015","name":"the University Hospital Basel","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016015","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100023287","name":"the Swiss Society for Endocrinology and Diabetology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023287","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the Hemmi Foundation"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>Arginine vasopressin (AVP) and oxytocin are neurohormones with opposing effects on bone in preclinical models, while their relevance in humans remains uncertain. Data on bone metabolism in individuals lacking AVP release\u2014and possibly also oxytocin\u2014such as patients with AVP deficiency (AVP-D, also known as central diabetes insipidus) remain scarce, although the limited available evidence suggests a potentially deleterious effect.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aimed to evaluate bone turnover markers in patients with AVP-D compared to individuals with primary polydipsia (PP) and healthy controls (HC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a secondary analysis of the prospective URANOS Trial (NCT05890690) conducted from June 2023 to June 2024. After excluding patients on chronic steroid therapy (except budesonide and replacement therapy), prior osteoporotic fractures, long-term antiresorptive treatment, or medications known to adversely affect bone metabolism (eg, aromatase inhibitors), 46 participants were included (HC = 22, AVP-D = 11, PP = 13). All individuals were assessed for bone resorption (C-terminal telopeptide of type I collagen [CTX]) and bone formation (N-terminal propeptide of type I collagen [P1NP]) markers, as well as 25OH-vitamin D, serum calcium, and phosphate. The bone formation index (defined as P1NP\/CTX ratio) was calculated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Serum calcium, phosphate, and P1NP levels were comparable across groups, whereas 25OH-vitamin D concentrations were lower in patients with AVP-D than in HC (P = .031). Median CTX levels were lower in AVP-D (0.373 [0.288-0.513] ng\/mL) than in HC (0.592 [0.427-0.729] ng\/mL, P = .021), with no difference between PP (0.514 [0.411-0.618] ng\/mL) and the other groups. The bone formation index was higher in AVP-D than in HC (P = .036), whereas no difference was observed between PP and either group. In the multivariable linear regression model adjusted for confounders, CTX was lower in AVP-D compared to HC (\u22120.183; 95% CI, \u22120.352 to \u22120.013; P = .036), with no difference compared to PP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Patients with AVP-D showed reduced CTX levels and consequently an increased P1NP\/CTX ratio compared to HC, whereas no difference was observed between patients with PP and both groups. Overall, these findings do not support major bone metabolic alterations with detrimental effects in AVP-D.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/clinem\/dgag001","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T12:18:48Z","timestamp":1767615528000},"page":"e1523-e1531","source":"Crossref","is-referenced-by-count":0,"title":["Bone turnover in arginine vasopressin deficiency: a comparative study with primary polydipsia and healthy controls"],"prefix":"10.1210","volume":"111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3772-8586","authenticated-orcid":false,"given":"Emanuele","family":"Varaldo","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Diabetology and Metabolism, University Hospital Basel , Basel 4031 ,","place":["Switzerland"]},{"name":"Department of Clinical Research, University Hospital Basel, University of Basel , Basel 4031 ,","place":["Switzerland"]},{"name":"Division of Endocrinology, Diabetology and Metabolism, Department of Medical Sciences, University of Turin , Turin 10126 ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2091-8460","authenticated-orcid":false,"given":"Sven","family":"Lustenberger","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetology and Metabolism, University Hospital Basel , Basel 4031 ,","place":["Switzerland"]},{"name":"Department of Clinical Research, University Hospital Basel, University of Basel , Basel 4031 ,","place":["Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5442-7304","authenticated-orcid":false,"given":"Cihan","family":"Atila","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetology and Metabolism, University Hospital Basel , Basel 4031 ,","place":["Switzerland"]},{"name":"Department of Clinical Research, University Hospital Basel, University of Basel , Basel 4031 ,","place":["Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0179-7889","authenticated-orcid":false,"given":"Sophie","family":"Monnerat","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetology and Metabolism, University Hospital Basel , Basel 4031 ,","place":["Switzerland"]},{"name":"Department of Clinical Research, University Hospital Basel, University of Basel , Basel 4031 ,","place":["Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4741-1483","authenticated-orcid":false,"given":"Laura","family":"Potasso","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetology and Metabolism, University Hospital Basel , Basel 4031 ,","place":["Switzerland"]},{"name":"Department of Clinical Research, University Hospital Basel, University of Basel , Basel 4031 ,","place":["Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6336-0965","authenticated-orcid":false,"given":"Mirjam","family":"Christ-Crain","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetology and Metabolism, University Hospital Basel , Basel 4031 ,","place":["Switzerland"]},{"name":"Department of Clinical Research, University Hospital Basel, University of Basel , Basel 4031 ,","place":["Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","published-online":{"date-parts":[[2026,1,7]]},"reference":[{"issue":"9","key":"2026051819574774400_dgag001-B1","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/nrn3044","article-title":"Oxytocin and vasopressin in the human brain: social neuropeptides for translational medicine","volume":"12","author":"Meyer-Lindenberg","year":"2011","journal-title":"Nat Rev Neurosci"},{"issue":"2","key":"2026051819574774400_dgag001-B2","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1515\/hmbci-2016-0015","article-title":"Pituitary-bone connection in skeletal regulation","volume":"28","author":"Zaidi","year":"2016","journal-title":"Horm Mol Biol Clin Investig"},{"issue":"6","key":"2026051819574774400_dgag001-B3","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s11102-024-01447-3","article-title":"Skeletal fragility in pituitary disease: how can we predict fracture risk?","volume":"27","author":"Bioletto","year":"2024","journal-title":"Pituitary"},{"issue":"46","key":"2026051819574774400_dgag001-B4","doi-asserted-by":"crossref","first-page":"18644","DOI":"10.1073\/pnas.1318257110","article-title":"Regulation of bone remodeling by vasopressin explains the bone loss in hyponatremia","volume":"110","author":"Tamma","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2026051819574774400_dgag001-B5","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1073\/pnas.1523762113","article-title":"Functions of vasopressin and oxytocin in bone mass regulation","volume":"113","author":"Sun","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"2026051819574774400_dgag001-B6","doi-asserted-by":"crossref","first-page":"3181","DOI":"10.1210\/jc.2018-02608","article-title":"Low plasma oxytocin levels and increased psychopathology in hypopituitary men with diabetes insipidus","volume":"104","author":"Aulinas","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2026051819574774400_dgag001-B7","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/S2213-8587(23)00120-1","article-title":"Oxytocin in response to MDMA provocation test in patients with arginine vasopressin deficiency (central diabetes insipidus): a single-centre, case-control study with nested, randomised, double-blind, placebo-controlled crossover trial","volume":"11","author":"Atila","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"2026051819574774400_dgag001-B8","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/s41574-024-00985-x","article-title":"Arginine vasopressin deficiency: diagnosis, management and the relevance of oxytocin deficiency","volume":"20","author":"Atila","year":"2024","journal-title":"Nat Rev Endocrinol"},{"issue":"7","key":"2026051819574774400_dgag001-B9","first-page":"2275","article-title":"Impairment of bone status in patients with central diabetes insipidus","volume":"83","author":"Pivonello","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2026051819574774400_dgag001-B10","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1210\/jcem.84.7.5816","article-title":"Effect of a short-term treatment with alendronate on bone density and bone markers in patients with central diabetes insipidus","volume":"84","author":"Pivonello","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"issue":"1-2","key":"2026051819574774400_dgag001-B11","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1159\/000506638","article-title":"Lower oxytocin levels are associated with lower bone mineral density and less favorable hip geometry in hypopituitary men","volume":"111","author":"Aulinas","year":"2020","journal-title":"Neuroendocrinology"},{"issue":"4","key":"2026051819574774400_dgag001-B12","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1093\/ejendo\/lvaf058","article-title":"Urea-stimulated copeptin: a novel diagnostic approach in polyuria polydipsia syndrome","volume":"192","author":"Lustenberger","year":"2025","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"2026051819574774400_dgag001-B13","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1136\/thx.54.3.223","article-title":"One year prospective open study of the effect of high dose inhaled steroids, fluticasone propionate, and budesonide on bone markers and bone mineral density","volume":"54","author":"Hughes","year":"1999","journal-title":"Thorax"},{"issue":"15","key":"2026051819574774400_dgag001-B14","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1056\/NEJM200010123431501","article-title":"Long-term effects of budesonide or nedocromil in children with asthma","volume":"343","author":"Childhood Asthma Management Program Research Group","year":"2000","journal-title":"N Engl J Med"},{"issue":"5","key":"2026051819574774400_dgag001-B15","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1046\/j.1365-2036.1998.00321.x","article-title":"Bone turnover during short-term therapy with methylprednisolone or budesonide in Crohn's disease","volume":"12","author":"D\u2019Haens","year":"1998","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"2026051819574774400_dgag001-B16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1530\/EJE-21-0604","article-title":"Effect of hyponatremia normalization on osteoblast function in patients with SIAD","volume":"186","author":"Potasso","year":"2022","journal-title":"Eur J Endocrinol"},{"issue":"10","key":"2026051819574774400_dgag001-B17","doi-asserted-by":"crossref","first-page":"e1027","DOI":"10.1210\/clinem\/dgad238","article-title":"An increase in plasma sodium levels is associated with an increase in osteoblast function in chronic SIAD","volume":"108","author":"Monnerat","year":"2023","journal-title":"J Clin Endocrinol Metabol"},{"key":"2026051819574774400_dgag001-B18","volume-title":"R: A Language and Environment for Statistical Computing","author":"R Core Team","year":"2024"},{"issue":"17","key":"2026051819574774400_dgag001-B19","doi-asserted-by":"crossref","first-page":"7149","DOI":"10.1073\/pnas.0901890106","article-title":"Oxytocin is an anabolic bone hormone","volume":"106","author":"Tamma","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"2026051819574774400_dgag001-B20","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1359\/jbmr.2001.16.2.398","article-title":"The influence of growth hormone deficiency, growth hormone replacement therapy, and other aspects of hypopituitarism on fracture rate and bone mineral density","volume":"16","author":"W\u00fcster","year":"2001","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2026051819574774400_dgag001-B21","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1530\/EJE-13-0596","article-title":"Low-dose hydrocortisone replacement therapy is associated with improved bone remodelling balance in hypopituitary male patients","volume":"170","author":"Behan","year":"2014","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"2026051819574774400_dgag001-B22","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1210\/er.2018-00005","article-title":"Pituitary diseases and bone","volume":"39","author":"Mazziotti","year":"2018","journal-title":"Endocr Rev"},{"issue":"2","key":"2026051819574774400_dgag001-B23","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.ecl.2022.11.002","article-title":"Age-associated abnormalities of water homeostasis","volume":"52","author":"Cowen","year":"2023","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"5","key":"2026051819574774400_dgag001-B24","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1007\/s11102-024-01454-4","article-title":"Desmopressin dose requirements in patients with permanent arginine vasopressin deficiency: a tertiary center experience","volume":"27","author":"Varaldo","year":"2024","journal-title":"Pituitary"},{"issue":"4","key":"2026051819574774400_dgag001-B25","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1210\/jc.2015-4228","article-title":"Association between hyponatremia, osteoporosis, and fracture: a systematic review and meta-analysis","volume":"101","author":"Upala","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"2026051819574774400_dgag001-B26","doi-asserted-by":"publisher","first-page":"102028","DOI":"10.1016\/j.beem.2025.102028","article-title":"Hyponatremia and bone pathophysiology: an integrated preclinical and clinical perspective","author":"Varaldo","year":"2025","journal-title":"Best Pract Res Clin Endocrinol Metabol"},{"issue":"10","key":"2026051819574774400_dgag001-B27","doi-asserted-by":"crossref","first-page":"3527","DOI":"10.1210\/jc.2014-1572","article-title":"Recovery from SIADH-associated osteoporosis: a case report","volume":"99","author":"Sejling","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"2026051819574774400_dgag001-B28","doi-asserted-by":"crossref","first-page":"1206235","DOI":"10.1155\/2018\/1206235","article-title":"The effect of tobacco smoking on bone mass: an overview of pathophysiologic mechanisms","volume":"2018","author":"Al-Bashaireh","year":"2018","journal-title":"J Osteoporos"},{"issue":"11","key":"2026051819574774400_dgag001-B29","doi-asserted-by":"crossref","first-page":"e0225539","DOI":"10.1371\/journal.pone.0225539","article-title":"Smoking and other determinants of bone turnover","volume":"14","author":"Jorde","year":"2019","journal-title":"PLoS One"},{"issue":"9","key":"2026051819574774400_dgag001-B30","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1007\/s00198-017-4082-4","article-title":"Use of CTX-I and PINP as bone turnover markers: National Bone Health Alliance recommendations to standardize sample handling and patient preparation to reduce pre-analytical variability","volume":"28","author":"Szulc","year":"2017","journal-title":"Osteoporos Int"},{"key":"2026051819574774400_dgag001-B31","volume-title":"StatPearls","author":"Williams","year":"2025"},{"issue":"1","key":"2026051819574774400_dgag001-B32","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s40364-017-0097-4","article-title":"Bone biomarker for the clinical assessment of osteoporosis: recent developments and future perspectives","volume":"5","author":"Kuo","year":"2017","journal-title":"Biomark Res"},{"issue":"3","key":"2026051819574774400_dgag001-B33","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1210\/endrev\/bnac031","article-title":"Bone turnover markers: basic biology to clinical applications","volume":"44","author":"Schini","year":"2023","journal-title":"Endocr Rev"},{"key":"2026051819574774400_dgag001-B34","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.bone.2019.04.002","article-title":"Effects of vitamin D supplementation on bone turnover markers and other bone-related substances in subjects with vitamin D deficiency","volume":"124","author":"Jorde","year":"2019","journal-title":"Bone"},{"issue":"3","key":"2026051819574774400_dgag001-B35","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1055\/s-0029-1211456","article-title":"Lower serum 25-hydroxyvitamin D is associated with increased bone resorption markers and lower bone density at the proximal femur in normal females: a population-based study","volume":"104","author":"Scharla","year":"1996","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"1","key":"2026051819574774400_dgag001-B36","doi-asserted-by":"crossref","first-page":"18138","DOI":"10.1038\/srep18138","article-title":"Associations between serum 25-hydroxyvitamin D and bone turnover markers in a population based sample of German children","volume":"5","author":"Thiering","year":"2016","journal-title":"Sci Rep"},{"issue":"5","key":"2026051819574774400_dgag001-B37","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s12603-020-1362-z","article-title":"Clinical research of the application of bone turnover markers in monitoring the short-term therapeutic efficacy of vitamin D in postmenopausal osteoporotic women in Harbin, China","volume":"24","author":"Zhang","year":"2020","journal-title":"J Nutr Health Aging"},{"issue":"1","key":"2026051819574774400_dgag001-B38","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4103\/ijem.IJEM_149_18","article-title":"Effect of vitamin D supplementation on bone turnover markers in children and adolescents from North India","volume":"23","author":"Marwaha","year":"2019","journal-title":"Indian J Endocrinol Metab"},{"issue":"3","key":"2026051819574774400_dgag001-B39","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.bbrc.2011.06.158","article-title":"Regulated production of the pituitary hormone oxytocin from murine and human osteoblasts","volume":"411","author":"Colaianni","year":"2011","journal-title":"Biochem Biophys Res Commun"},{"issue":"34","key":"2026051819574774400_dgag001-B40","doi-asserted-by":"crossref","first-page":"29159","DOI":"10.1074\/jbc.M112.365049","article-title":"Bone marrow oxytocin mediates the anabolic action of estrogen on the skeleton","volume":"287","author":"Colaianni","year":"2012","journal-title":"J Biol Chem"},{"key":"2026051819574774400_dgag001-B41","doi-asserted-by":"crossref","first-page":"1171732","DOI":"10.3389\/fphar.2023.1171732","article-title":"The mechanism of oxytocin and its receptors in regulating cells in bone metabolism","volume":"14","author":"Feixiang","year":"2023","journal-title":"Front Pharmacol"},{"issue":"16","key":"2026051819574774400_dgag001-B42","doi-asserted-by":"crossref","first-page":"8551","DOI":"10.3390\/ijms22168551","article-title":"Oxytocin and bone: review and perspectives","volume":"22","author":"Breuil","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"4","key":"2026051819574774400_dgag001-B43","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1210\/en.2013-1688","article-title":"Oxytocin reverses ovariectomy-induced osteopenia and body fat gain","volume":"155","author":"Beranger","year":"2014","journal-title":"Endocrinology"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgag001\/66294980\/dgag001.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/111\/6\/e1523\/66294980\/dgag001.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/111\/6\/e1523\/66294980\/dgag001.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T23:58:02Z","timestamp":1779148682000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/111\/6\/e1523\/8416619"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,7]]},"references-count":43,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,1,7]]},"published-print":{"date-parts":[[2026,5,19]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgag001","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,1,7]]}}}